Orbimed Advisors LLC Invests $5.53 Million in Artivion, Inc. $AORT

Orbimed Advisors LLC purchased a new stake in shares of Artivion, Inc. (NYSE:AORT) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 151,000 shares of the company’s stock, valued at approximately $5,530,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Verition Fund Management LLC boosted its holdings in Artivion by 1.6% during the third quarter. Verition Fund Management LLC now owns 16,912 shares of the company’s stock worth $716,000 after buying an additional 274 shares in the last quarter. Entropy Technologies LP grew its holdings in shares of Artivion by 6.0% during the fourth quarter. Entropy Technologies LP now owns 5,504 shares of the company’s stock valued at $251,000 after buying an additional 310 shares in the last quarter. Rockefeller Capital Management L.P. lifted its position in shares of Artivion by 150.0% in the fourth quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company’s stock worth $30,000 after purchasing an additional 399 shares in the last quarter. Arizona State Retirement System lifted its position in Artivion by 4.6% in the 4th quarter. Arizona State Retirement System now owns 11,235 shares of the company’s stock worth $512,000 after buying an additional 494 shares in the last quarter. Finally, Van ECK Associates Corp boosted its position in Artivion by 19.0% during the third quarter. Van ECK Associates Corp now owns 3,176 shares of the company’s stock valued at $134,000 after purchasing an additional 506 shares during the last quarter. 86.37% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Artivion news, SVP Andrew M. Green sold 44,001 shares of the stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $20.70, for a total value of $910,820.70. Following the sale, the senior vice president directly owned 60,259 shares in the company, valued at approximately $1,247,361.30. This trade represents a 42.20% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.30% of the company’s stock.

Artivion Price Performance

Artivion stock opened at $25.32 on Monday. The company has a current ratio of 3.86, a quick ratio of 2.80 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of $1.23 billion, a P/E ratio of 105.50 and a beta of 1.26. The business has a 50-day moving average of $22.68 and a 200-day moving average of $32.23. Artivion, Inc. has a 1 year low of $19.16 and a 1 year high of $48.25.

Analyst Ratings Changes

Several equities analysts have commented on AORT shares. Canaccord Genuity Group reissued a “buy” rating and set a $36.00 target price on shares of Artivion in a research report on Tuesday, June 16th. LADENBURG THALM/SH SH upgraded Artivion from a “neutral” rating to a “buy” rating and set a $42.00 price objective for the company in a research report on Friday, April 10th. Weiss Ratings lowered shares of Artivion from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, June 8th. Wall Street Zen lowered Artivion from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Finally, Citigroup reiterated a “market outperform” rating on shares of Artivion in a research note on Tuesday, July 21st. Seven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $44.17.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.